Alpha-Tocopherol Acetate
| 證據等級: L5 | 預測適應症: 10 個 |
目錄
- Alpha-Tocopherol Acetate
- Alpha-Tocopherol Acetate: From Antioxidant Supplement to Drug-Induced Osteoporosis
Alpha-Tocopherol Acetate: From Antioxidant Supplement to Drug-Induced Osteoporosis
One-Sentence Summary
Alpha-tocopherol acetate is the acetate ester form of Vitamin E (alpha-tocopherol), a fat-soluble antioxidant with no formally registered indications in Singapore. The TxGNN model ranks Drug-Induced Osteoporosis as its highest-scoring predicted new indication, with 0 clinical trials and 0 publications currently supporting this specific direction.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | No approved indications on record in Singapore |
| Predicted New Indication | Drug-Induced Osteoporosis |
| TxGNN Prediction Score | 99.99% |
| Evidence Level | L5 |
| Singapore Market Status | ✗ Not Marketed |
| Number of Registrations | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available from DrugBank for this submission. Based on well-established pharmacological knowledge, alpha-tocopherol acetate is the stable acetate ester form of Vitamin E. It is hydrolysed in the gut to release free alpha-tocopherol, the body's primary lipid-soluble chain-breaking antioxidant. Alpha-tocopherol terminates lipid peroxidation cascades in biological membranes by donating hydrogen atoms to peroxyl radicals, and it also modulates cell signalling through protein kinase C (PKC) inhibition.
Drug-induced osteoporosis — most commonly glucocorticoid-induced — operates primarily through suppression of osteoblast differentiation and proliferation, accelerated osteoclast-mediated bone resorption, and impaired calcium absorption. There is a plausible but indirect mechanistic link: oxidative stress is a recognised contributor to glucocorticoid-induced bone loss, and alpha-tocopherol's antioxidant properties could theoretically protect osteoblasts from reactive oxygen species (ROS)-mediated apoptosis. Animal studies have suggested Vitamin E may modestly improve bone turnover markers under oxidative stress conditions.
However, this connection is speculative. The TxGNN model's highest-scored prediction for this drug carries zero clinical or published literature support. The score is likely driven by knowledge graph node proximity between "Vitamin E / antioxidant" and the broad "osteoporosis" disease cluster, and may represent a model generalisation artefact. Notably, three other TxGNN predictions — diabetic retinopathy (L2, rank 10), cortical cataract (L3, rank 9), and diabetic cataract (L4, rank 2) — carry substantially stronger biological rationale and real-world evidence, and may represent more actionable candidates.
Clinical Trial Evidence
Currently no related clinical trials registered for drug-induced osteoporosis.
Literature Evidence
Currently no related literature available for drug-induced osteoporosis.
Singapore Market Information
Alpha-tocopherol acetate (DrugBank ID: DB14003) currently has no HSA product registrations in Singapore and is not marketed as a standalone pharmaceutical product.
| Authorization Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| — | No registered products found | — | — |
Safety Considerations
Please refer to the package insert for safety information.
Note: Package insert warnings, contraindications, and drug interaction data were not retrievable in this evidence pack (Data Gaps DG001 and DG002). These must be resolved before any safety assessment can proceed.
Conclusion and Next Steps
Decision: Hold
Rationale: Despite a near-perfect TxGNN prediction score (99.99%), the complete absence of clinical trials and published literature for drug-induced osteoporosis, combined with only an indirect mechanistic link, is inconsistent with advancing this candidate. The prediction is most likely a knowledge graph propagation artefact rather than a true biological signal.
To proceed, the following is needed:
- Resolve DG001 (Blocking): Retrieve Singapore HSA package insert to obtain warnings and contraindications — required before any S1 safety screen
- Resolve DG002 (High): Query DrugBank API for full MOA data to enable mechanistic linkage analysis
- Targeted literature search: Conduct a specific PubMed/Cochrane search for alpha-tocopherol AND corticosteroid-induced osteoporosis to confirm the evidence void
- Consider reprioritisation: The top-ranked TxGNN prediction (drug-induced osteoporosis, L5) is the weakest candidate in this evidence pack. The following indications carry meaningfully stronger evidence and may merit priority review:
- Diabetic Retinopathy (rank 10): L2 evidence — 2 completed clinical trials (Phase 2 & Phase 3) + 20 publications, mechanistically well-supported (PKC-β inhibition, lipid peroxidation suppression); decision stage S2, Proceed with Guardrails
- Cortical Cataract (rank 9): L3 evidence — 9 publications including 2 RCTs, strong mechanistic rationale (membrane lipid protection in lens cortex); decision stage S2, Research Question
- Diabetic Cataract (rank 2): L4 evidence — 11 publications, mechanistically plausible via oxidative stress pathway; decision stage S1, Research Question
⚠️ Disclaimer: This report is for research reference only and does not constitute medical advice. All drug repurposing candidates require clinical validation before any clinical application.
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.